Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma

Dermatologic Surgery

Volumn 31, Issue 2, 2005, Pages 217-220

  Peris, Ketty ^a   Ferrari, Angela ^a   Fargnoli, Maria Concetta ^a   Piccolo, Domenico ^a   Chimenti, Sergio ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; TAZAROTENE; DERMATOLOGICAL AGENT; NICOTINIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFICACY; EPILUMINESCENCE MICROSCOPY; ERYTHEMA; EXCISION; FACE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PRURITUS; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; CLINICAL TRIAL; GEL; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; MICROSCOPY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; DERMATOLOGIC AGENTS; FEMALE; GELS; HUMANS; MALE; MICROSCOPY; MIDDLE AGED; NICOTINIC ACIDS; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 15044360473     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200502000-00018     Document Type: Article

References (23)

1. Thissen MRTM, Neumann MHA, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177-83.
2. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999;141:415-23.
3. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999;341:1767-8.
4. Duvic M, Ni X, Talpur R, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003;121:902-9.
5. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Comparison of dosing regimens. Arch Dermatol 2002;138:1165-71.
6. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227-36.
7. Soyer HP, Smolle J, Hodl S, et al. Surface microscopy: a new approach to the diagnosis of cutaneous pigmented tumors. Am J Dermatopathol 1989;11:1-10.
8. Pehamberger H, Binder M, Steiner A, Wolff K. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993;100:356-62,
9. Stolz W, Braun-Falco O, Bilek P, et al. In: Color atlas of dermatoscopy. 2nd enlarged and completely revised, ed. Oxford (UK): Blackwell Science; 2002. p. 163-6.
10. Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions-a valuable tool for early diagnosis of melanoma. Lancet Oncol 2001;2:433-9.
11. Steiner A, Pehamberger H, Wolff K. In vivo epiluminescence of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol 1987;17:584-91.
12. Argenziano G, Soyer HP, De Giorgi V, et al. In: Interactive atlas of dermoscopy: a tutorial (book) and CD-ROM. Milan: Edra - Medical Publishing & New Media, 2000. p. 143-6.
13. Menzies SW, Westerhoff K, Rabinovitz H, et al. Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol 2000;136:1012-6.
14. Kraemer KH, Di Giovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
15. Lippman SM, Lotan R, Clayman GL. Systemic prevention and treatment of skin cancer. In: Weber RS, Miller MJ, Goepfert H, editors. Basal and squamous cancers of the head and neck. Baltimore: William and Williams; 1996. p. 351-5.
16. Bower CP, Lear JT, Bygrave S, et al. Basal cell carcinoma and risk of subsequent malignancies: a cancer registry based study in southwest England. J Am Acad Dermatol 2000;42:988-91.
17. Hofmann B, Stage H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999;141:642-6.
18. Micali G, Nasca MR. Tazarotene gel in childhood Darier disease. Pediatr Dermatol 1999;16:243-4.
19. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004;151:148-56.
20. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
21. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6-week dose-response trial. J Am Acad Dermatol 2001;44: 807-13.
22. Cowen E, Mercurio MG, Gaspari A. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002;47:240-8.
23. Haas N, Sterry W. The use of ELM to monitor the success of antiscabietic treatment. Arch Dermatol 2001;137:1656-7.